

Marek Brzosko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1283933/publications.pdf>

Version: 2024-02-01

67
papers

1,536
citations

430874

18
h-index

315739

38
g-index

69
all docs

69
docs citations

69
times ranked

2161
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of systemic steroids combined with immunosuppressive treatment on glaucomatous features in patients with systemic lupus erythematosus. <i>International Journal of Ophthalmology</i> , 2022, 15, 71-76.	1.1	0
2	Respiratory involvement in antineutrophil cytoplasmic antibody-associated vasculitides: a retrospective study based on POLVAS registry. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	1
3	Correspondence to "Slope sign": a feature of large vessel vasculitis?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e198-e198.	0.9	7
4	Serum interleukin-23 protects, whereas methotrexate treatment stimulates selected components of the metabolic syndrome in patients with SAPHO syndrome. <i>Archives of Medical Science</i> , 2021, 17, 120-126.	0.9	2
5	Axial spondyloarthritis and inflammatory bowel disease: association between disease activity and endothelial dysfunction markers. <i>Rheumatology International</i> , 2021, , 1.	3.0	5
6	An expert opinion of the Polish Cardiac Society Working Group on Pulmonary Circulation and the Polish Society for Rheumatology on the diagnosis and treatment of pulmonary hypertension in patients with connective tissue disease. <i>Kardiologia Polska</i> , 2021, 79, 917-929.	0.6	3
7	Real-World Data from a Multi-Center Study: Insights to Psoriatic Arthritis Care. <i>Journal of Clinical Medicine</i> , 2021, 10, 4106.	2.4	1
8	SAPHO syndrome: pathogenesis, clinical presentation, imaging, comorbidities and treatment: a review. <i>Postepy Dermatologii i Alergologii</i> , 2021, 38, 937-942.	0.9	15
9	Subphenotypes of ANCA-associated vasculitis identified by latent class analysis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 62-68.	0.8	1
10	Polymyalgia rheumatica without elevated baseline acute phase reactants. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 441.	0.8	0
11	Calcium pyrophosphate disease and polymyalgia reumatica: association or coincidence? Comment on "Ultrasound shoulder assessment of calcium pyrophosphate disease with suspected polymyalgia rheumatica" Ottaviani et al. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 920.	0.8	0
12	Subphenotypes of ANCA-associated vasculitis identified by latent class analysis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 62-68.	0.8	4
13	Polymyalgia rheumatica without elevated baseline acute phase reactants. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 441-441.	0.8	1
14	The relationship between work, mental health, physical health, and fatigue in patients with rheumatoid arthritis: A cross-sectional study. <i>Journal of Health Psychology</i> , 2020, 25, 665-673.	2.3	8
15	Familial aggregation of longevity in giant cell arteritis and polymyalgia rheumatica. <i>Rheumatology International</i> , 2020, 40, 2071-2075.	3.0	1
16	ANCA-associated vasculitis patients treated in Polish intensive care units " retrospective characteristics based on the POLVAS registry. <i>Anaesthesiology Intensive Therapy</i> , 2020, 52, 281-286.	1.0	2
17	Polymyalgia rheumatica with normal inflammatory indices at the time of diagnosis: can we just move a step forward?. <i>Reumatologia</i> , 2020, 58, 184-186.	1.1	3
18	Tunnel Vision in a Patient with Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2020, 47, 155-156.	2.0	1

#	ARTICLE	IF	CITATIONS
19	Treatment and its side effects in ANCA-associated vasculitides – Study based on POLVAS registry data. <i>Advances in Medical Sciences</i> , 2020, 65, 156-162.	2.1	13
20	Ormond’s disease accompanied by ankylosing spondylitis – a case report. <i>Pomeranian Journal of Life Sciences</i> , 2020, 66, 16-20.	0.1	0
21	Right atrial myxoma: a potential accelerator of pulmonary hypertension in the course of systemic sclerosis. The role of interleukin-6. <i>Postępy Dermatologii i Alergologii</i> , 2019, 36, 354-357.	0.9	4
22	Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis. <i>Rheumatology</i> , 2019, 58, 921-923.	1.9	23
23	Factors associated with quality of life in systemic sclerosis: a cross-sectional study. <i>Quality of Life Research</i> , 2019, 28, 3347-3354.	3.1	29
24	Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial. <i>BioDrugs</i> , 2019, 33, 79-91.	4.6	26
25	Monogenic autoinflammatory diseases in adults – a challenge to rheumatologic practice at the onset of the Polish national programme of interleukin 1 inhibitor treatment. <i>Reumatologia</i> , 2019, 57, 326-335.	1.1	2
26	Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 258-270.	5.6	237
27	Clinical manifestations of neuropsychiatric systemic lupus erythematosus in Polish patients: a single centre study from West-Pomeranian Region of Poland. <i>Polish Archives of Internal Medicine</i> , 2019, 130, 82-84.	0.4	2
28	Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology. <i>Reumatologia</i> , 2018, 56, 203-211.	1.1	21
29	Biosimilar switching – current state of knowledge. <i>Reumatologia</i> , 2018, 56, 234-242.	1.1	33
30	Novel Approach to the Treatment in Rheumatic Diseases: From Molecule to Value for Patient. <i>BioMed Research International</i> , 2018, 2018, 1-1.	1.9	0
31	Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 346-354.	0.9	204
32	Results from Polish Spondyloarthritis Initiative registry (PolSPI) – methodology and data from the first year of observation. <i>Reumatologia</i> , 2017, 2, 59-64.	1.1	0
33	Serum Interleukin-23 in Polish Patients with Systemic Lupus Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral Vascular Disease. <i>Mediators of Inflammation</i> , 2017, 2017, 1-9.	3.0	25
34	Diagnosis of polymyalgia rheumatica usually means a favourable outcome for your patient. <i>Indian Journal of Medical Research</i> , 2017, 145, 593-600.	1.0	9
35	Extra-Articular Symptoms in Constellation with Selected Serum Cytokines and Disease Activity in Spondyloarthritis. <i>Mediators of Inflammation</i> , 2016, 2016, 1-7.	3.0	22
36	Serum Interleukin-18, Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1255.	4.1	33

#	ARTICLE	IF	CITATIONS
37	Serum VEGF, EGF, basic FGF, and acidic FGF levels and their association with disease activity and extra-articular symptoms in ankylosing spondylitis. Polish Archives of Internal Medicine, 2016, , .	0.4	2
38	Serum VEGF, EGF, basic FGF, and acidic FGF levels and their association with disease activity and extra-articular symptoms in ankylosing spondylitis. Polish Archives of Internal Medicine, 2016, 126, 290-2.	0.4	13
39	Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial. Clinical and Experimental Rheumatology, 2016, 34, 625-33.	0.8	18
40	Antiphospholipid Syndrome with Anti-β ₂ glycoprotein-1 Antibodies as the Cause of Recurrent Tibial Vein Thrombosis in SAPHO syndrome. Acta Dermatovenerologica Croatica, 2016, 24, 305-306.	0.1	2
41	Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. Mediators of Inflammation, 2015, 2015, 1-7.	3.0	38
42	271. The Evaluation of Atherosclerotic Changes in Systemic Lupus Erythematosus Patients: The Diagnostic and Prognostic Value of Selected Noninvasive Imaging Techniques. Rheumatology, 2014, 53, i160-i161.	1.9	0
43	PTPN22 1858C>T gene polymorphism in patients with SLE: association with serological and clinical results. Molecular Biology Reports, 2014, 41, 6195-6200.	2.3	18
44	Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results. Journal of Rheumatology, 2013, 40, 113-126.	2.0	87
45	Serum levels of angiogenic cytokines in psoriatic arthritis and SAPHO syndrome. Polish Archives of Internal Medicine, 2013, 123, 297-302.	0.4	21
46	Arteriosclerosis or Vasculitis? Color Duplex Sonography in Giant Cell Arteritis. Journal of Rheumatology, 2012, 39, 1898-1899.	2.0	4
47	Polyarteritis nodosa and Sjögren's syndrome: overlap syndrome. Rheumatology International, 2012, 32, 4019-4021.	3.0	4
48	Estimation of vascular endothelial growth factor and placental growth factor serum levels' in infant with hemangioma and population of healthy infants. Annales Academiae Medicae Stetinensis, 2012, 58, 5-10.	0.1	1
49	Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu. Arthritis and Rheumatism, 2011, 63, 609-621.	6.7	369
50	Single- versus dual-infusion of B-cell-depleting antibody ocrelizumab in rheumatoid arthritis: results from the Phase III FEATURE trial. International Journal of Clinical Rheumatology, 2011, 6, 689-696.	0.3	5
51	Diagnosis of early atherosclerotic lesions, and selected atherosclerotic risk factors, in patients with systemic lupus erythematosus. Polish Archives of Internal Medicine, 2009, 119, 736-742.	0.4	4
52	Familial association of laryngeal, lung, stomach and early-onset breast cancer. Breast Cancer Research and Treatment, 2008, 112, 359-361.	2.5	0
53	Comment on "Polymyalgia rheumatica as the manifestation of unclassified aortitis". Modern Rheumatology, 2008, 18, 427-428.	1.8	3
54	Comment on "Polymyalgia rheumatica as the manifestation of unclassified aortitis". Modern Rheumatology, 2008, 18, 427-428.	1.8	3

#	ARTICLE	IF	CITATIONS
55	Chorea as a rare symptom of systemic lupus erythematosus in the elderly. Polish Archives of Internal Medicine, 2008, 118, 75-79.	0.4	1
56	Cardiac Arrhythmias and Conduction Disturbances in Patients With Ankylosing Spondylitis. Angiology, 2007, 58, 751-756.	1.8	33
57	Chronic Urticaria and Mild Arthritis Associated with Autoimmune Thyroid Disease: Successful Treatment with L-Thyroxine. Acta Dermato-Venereologica, 2007, 87, 263-264.	1.3	2
58	Association between early-onset breast and laryngeal cancers. Breast Cancer Research and Treatment, 2006, 97, 215-219.	2.5	10
59	Rhythm Disturbances in the Form of Atrial Tachycardia in a Female Patient with Polymyositis. Angiology, 2006, 57, 391-394.	1.8	6
60	Fungal spondylodiscitis in a patient with ulcerative colitis - case report. Ortopedia Traumatologia Rehabilitacja, 2006, 8, 708-13.	0.3	1
61	Efficacy and tolerability of lumiracoxib 100mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Current Medical Research and Opinion, 2005, 21, 517-526.	1.9	72
62	Normal profile of sex hormones in women with primary fibromyalgia. Annales Academiae Medicae Stetinensis, 2005, 51, 23-6.	0.1	12
63	The urinary excretion of pyridinoline and deoxypyridinoline during rheumatoid arthritis therapy with infliximab. Clinical Rheumatology, 2004, 23, 214-217.	2.2	13
64	Therapy with infliximab decreases the CD4+CD28? T cell compartment in peripheral blood in patients with rheumatoid arthritis. Rheumatology International, 2004, 24, 351-354.	3.0	21
65	Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations. Journal of Applied Genetics, 2004, 45, 255-63.	1.9	5
66	Nuclear Pedigree Criteria of Suspected HNPCC. Hereditary Cancer in Clinical Practice, 2003, 1, 1.	1.5	8
67	Increased genotype frequency of N-acetyltransferase 2 slow acetylation in patients with rheumatoid arthritis. Clinical Pharmacology and Therapeutics, 2002, 72, 319-325.	4.7	20